Name: KINIKSA PHARMACEUTICALS INTE (KNSA) Stock
Brand: KINIKSA PHARMACEUTICALS INTE
Rating: 8 (3 reviews)

KNSA Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

21 days ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

a month ago - By: Benzinga

5 Analysts Have This To Say About Kiniksa Pharmaceuticals

a month ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

2 months ago - By: Benzinga

What Analysts Are Saying About Kiniksa Pharmaceuticals Stock

2 months ago - By: Zacks Investment Research - Mentions: ZTS CRMD PHAR

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

2 months ago - By: Zacks Investment Research - Mentions: RARE CRMD PHAR

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

2 months ago - By: Zacks Investment Research - Mentions: CRMD IMVT PHAR

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

2 months ago - By: Zacks Investment Research - Mentions: BMY CYTK CRMD

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

2 months ago - By: Zacks Investment Research - Mentions: CRMD EDIT PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

2 months ago - By: Zacks Investment Research

Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why

2 months ago - By: Zacks Investment Research - Mentions: POST TME

Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA?

2 months ago - By: Zacks Investment Research - Mentions: ALNY CRMD

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

3 months ago - By: Zacks Investment Research - Mentions: CRMD OTLK PHAR

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

3 months ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research - Mentions: INO CRMD PGEN

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

3 months ago - By: Zacks Investment Research - Mentions: CPRX CRMD PHAR

Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

3 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade

3 months ago - By: Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why

3 months ago - By: Zacks Investment Research - Mentions: TPC ESEA MOD LIF

Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas

3 months ago - By: Zacks Investment Research - Mentions: GSK TBPH CRMD

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

3 months ago - By: Zacks Investment Research - Mentions: TPC ESEA MOD LIF

5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties

3 months ago - By: Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know

3 months ago - By: Investor's Business Daily - Mentions: GILD AUPH INCY

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

3 months ago - By: Zacks Investment Research

Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge

3 months ago - By: Zacks Investment Research

Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?

3 months ago - By: Zacks Investment Research

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

4 months ago - By: Kiniksa Pharmaceuticals International, Plc

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock News

KNSA Latest News, Press Relases and Analysis

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

5 Analysts Have This To Say About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

What Analysts Are Saying About Kiniksa Pharmaceuticals Stock

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why

Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA?

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade

Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties

Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge

Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution